Q1 2025 Earnings Call May 6, 2025 IQVIA Template (V2.1.0) 100% 50% 75% 25% 1 Legal This presentation should be viewed in conjunction with IQVIA's Q1 2025 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our second-quarter a ...

Core Viewpoint - Streamline Health Solutions, Inc. reported a decline in revenue for the fourth quarter and fiscal year 2024, primarily due to SaaS non-renewals and lower revenue from legacy contracts, while emphasizing a focus on innovation and client engagement to drive future growth [1][3][4]. Financial Performance - Total revenue for Q4 2024 was $4.7 million, down from $5.4 million in Q4 2023. For the fiscal year, revenue totaled $17.9 million compared to $22.6 million in the previous year [3]. - SaaS revenue for Q4 2024 was $3.1 million, representing 66% of total revenue, compared to $3.4 million (64%) in Q4 2023. For the fiscal year, SaaS revenue was $11.8 million (66%) versus $14.1 million (62%) in fiscal 2023 [4]. - The net loss for Q4 2024 was ($2.1 million), compared to a net loss of ($1.4 million) in Q4 2023. The total net loss for fiscal 2024 was ($10.2 million), an improvement from ($18.7 million) in fiscal 2023 [5]. Cash Position and Liabilities - Cash and cash equivalents as of January 31, 2025, were $2.2 million, down from $3.2 million a year earlier. The company had an outstanding balance of $1.0 million on its revolving credit facility [6]. - Total liabilities increased to $23.3 million as of January 31, 2025, compared to $22.9 million in the previous year [23]. Adjusted EBITDA - Adjusted EBITDA for Q4 2024 was $35,000, down from $0.4 million in Q4 2023. For the fiscal year, adjusted EBITDA was a loss of ($1.3 million), slightly improved from a loss of ($1.4 million) in fiscal 2023 [7][28]. Booked SaaS Annual Contract Value (ACV) - As of January 31, 2025, the total Booked SaaS ACV was $14.0 million, down from $15.0 million a year earlier, largely due to client non-renewals, but offset by $3.5 million in new bookings during fiscal 2025 [8][9]. Future Outlook - The company expects to achieve an adjusted EBITDA positive run rate during the first half of fiscal 2025, although specific guidance on timing for bookings has not been provided due to unpredictability [11].

Financial Data and Key Metrics Changes - Total revenue for full year 2024 was $307 million, representing a 4% year-over-year growth, while adjusted EBITDA was $26 million, reflecting a 137% increase year-over-year [17][56] - For Q4 2024, total revenue was $80 million, a 6% increase year-over-year, and adjusted EBITDA was $8 million, above the midpoint of guidance [56][61] - Technology revenue for full year 2024 was $195 million, with Q4 2024 revenue at $52 million, marking a 10% growth year-over-year for the quarter [17][56] Business Line Data and Key Metrics Changes - Technology segment revenue for full year 2024 grew by 4% year-over-year, while professional services revenue was $112 million, representing a 3% increase year-over-year [56][58] - Adjusted gross margin for the Technology segment in Q4 2024 was 65%, a decrease of approximately 200 basis points year-over-year, primarily due to initial deployment costs [58][59] - Professional services segment adjusted gross margin for Q4 2024 was 13%, an increase of approximately 170 basis points year-over-year [59] Market Data and Key Metrics Changes - Health system operating margins are stabilizing and approaching pre-pandemic levels, which is expected to positively impact client adoption of the company's applications [33] - The company anticipates approximately 40 net new platform client additions in 2025, with an average range of $300,000 to $700,000 ARR plus nonrecurring revenue [35][39] Company Strategy and Development Direction - The company is focusing on profitable growth, with an emphasis on technology revenue, which is expected to grow approximately 13% year-over-year in 2025 [69] - The company plans to exit unprofitable ambulatory operations TEMS pilots by mid-2025 to prioritize profitable growth [37][69] - The modular and flexible Ignite platform is expected to drive cross-selling opportunities and improve client retention [78][121] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the operating environment, noting improvements in health system operating margins and the potential for increased client adoption of applications [33][78] - The company expects to see improvements in bookings metrics compared to 2024, driven by the strengthening end market and continued momentum from Ignite [34][39] - Management anticipates that dollar-based retention rate will be approximately 103% under the updated definition for 2025 [36][88] Other Important Information - The company ended Q4 2024 with $392 million in cash and cash equivalents, compared to $387 million in Q3 2024 [63] - The company has made several leadership updates, including the appointment of Dr. Jill Hoggard Green to the Board of Directors [47][50] Q&A Session Summary Question: What is driving the acceleration in platform bookings in 2025? - Management highlighted improvements in the end market, the modularity and lower price point of Ignite compared to DOS, and the ability to cross-sell to existing app clients as key factors driving the expected increase in platform bookings [76][78] Question: Can you discuss the differences in the new Ignite platform versus DOS regarding annual escalators? - Management noted that Ignite contracts typically have more modest annual escalators in the low to mid-single-digit range, making them easier for clients to digest [82][84] Question: How do you control the pace of migrations to Ignite? - Management is working closely with clients to manage the migration pace responsibly, aiming to complete the majority of migrations by mid-2026 [90][92] Question: What is the visibility into growth in technology revenue after Q1? - Management indicated good visibility into technology revenue growth, estimating approximately 10% year-over-year growth for Q1 2025 [130]

As filed with the Securities and Exchange Commission on February 12, 2024 Registration No. 333-276501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTHCARE TRIANGLE, INC. (Exact name of registrant as specified in its charter) | Delaware | | --- | (State or other jurisdiction of incorporation or organization) Delaware 7373 84-3559776 (Primary Standard Industrial Classification Code Number) (I.R.S. ...

As filed with the Securities and Exchange Commission on February 9, 2024 Registration No. 333-276501 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTHCARE TRIANGLE, INC. (Exact name of registrant as specified in its charter) | Delaware | | --- | Delaware 7373 84-3559776 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. ...

As filed with the Securities and Exchange Commission on January 12, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 HEALTHCARE TRIANGLE, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 7373 84-3559776 (I.R.S. Employer Identification Number) 7901 Stoneridg ...